A 364
Latest Information Update: 03 May 2004
Price :
$50 *
At a glance
- Originator Arrow Therapeutics
- Class Antibacterials
- Mechanism of Action Dehydroquinate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 03 May 2004 Discontinued - Preclinical for Gram-positive infections in United Kingdom (unspecified route)
- 13 Jan 2002 New profile
- 13 Jan 2002 Preclinical development for Gram-positive infections in United Kingdom (Unknown route)